Article
MAP2K1 Mutations in Advanced Colorectal Cancer Predict Poor Response to Anti-EGFR Therapy and to Vertical Targeting of MAPK Pathway.
Clinical colorectal cancer - 1 Mar 2021
Chuang Jeremy, Wang Chongkai, Guo Yuming, Valenzuela Valerie, Wu Jun, Fakih Marwan
Abstract excerpt
BACKGROUND: MAP2K1 mutations, otherwise known as MEK mutations, are rare oncogenic alterations that have been implicated in MAPK pathway activation. The impact of MAP2K1 mutations in colorectal cancer on EGFR antibody response has not been characterized. PATIENTS AND METHODS: Antitumor activity was assessed in mouse xenograft models with SW48 cell lines harboring MAP2K1 mutation, and protein expression of the RAS...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.